Piper Sandler Downgrades enGene Therapeutics to Neutral, Lowers Price Target to $4

Benzinga Newsdesk www.benzinga.com Negative 91.6%

Neg 91.6% Neu 0% Pos 0%

Piper Sandler analyst Allison Bratzel downgrades enGene Therapeutics (NASDAQ:ENGN) from Overweight to Neutral and lowers the price target from $7 to $4.